期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

miR-802和RAB23在前列腺癌中的表达水平及与临床病理特征和预后的相关性 认领

The expression level of miR-802 and RAB23 in prostate cancer and their relationships with clinicopathological features and prognosis
在线阅读 下载PDF
收藏 分享 导出
摘要 目的:检测前列腺癌患者肿瘤组织中微小RNA(miRNA)及RAB23表达水平,分析其与临床病理特征及预后的关系。方法:选取2011年2月至2014年2月本院确诊并进行前列腺根治手术治疗的前列腺癌患者150例为研究对象,选择同期因良性前列腺增生行电切手术的患者150例为对照组,利用免疫组化法(SP)检测组织中RAB23表达情况,利用实时定量PCR(quantitative reverse transcription-PCR,qRT-PCR)检测组织中miR-802及RAB23 mRNA表达水平。结果:前列腺癌肿瘤组织较前列腺增生组织中miR-802表达水平降低(P<0.05),RAB23 mRNA及蛋白表达水平升高(P<0.05);前列腺癌患者肿瘤组织中miR-802及RAB23表达情况与患者T分期、淋巴结转移、Gleason评分、PSA水平有关(P<0.05);Kaplan-Meier生存分析表明,miR-802高表达患者3年总生存率高于miR-802低表达者(P<0.05);RAB23高表达患者3年总生存率显著低于RAB23低表达者(P<0.05);多因素分析表明,高Gleason评分、miR-802低表达、RAB23高表达是影响患者不良预后的独立危险因素(P<0.05);肿瘤组织miR-802及RAB23 mRNA表达水平负相关(P<0.05)。结论:前列腺癌肿瘤组织中miR-802低表达,RAB23蛋白高表达,均与患者T分期、淋巴结转移、Gleason评分、PSA水平、3年总生存率有关,高Gleason评分、miR-802低表达、RAB23高表达是影响患者不良预后的独立危险因素。 Objective:To detect the expressions of microRNA(miRNA)and RAB23 in prostate cancer tissues,and to analyze their relationships with clinicopathological features and prognosis.Methods:150 patients with prostate cancer who were diagnosed and treated by radical prostatectomy in our hospital from February 2011 to February 2014 were selected as the study subjects.150 patients with benign prostatic hyperplasia who underwent electrosurgical resection at the same time were selected as the control group.The expression of RAB23 in tissues was detected by immunohistochemistry(SP).Real-time quantitative polymerase chain reaction(qRT-PCR)was used to detect the expressions of miR-802 and RAB23 in tissues.Results:The expression of microRNA-802 in prostate cancer was lower than that in benign prostatic hyperplasia(P<0.05),and the expressions of RAB23 mRNA and protein were higher(P<0.05).The expressions of miR-802 and RAB23 in prostate cancer tissues were correlated with T stage,lymph node metastasis,Gleason score and PSA level(P<0.05).Kaplan-Meier survival analysis showed that the 3-year overall survival rate of patients with high expression of miR-802 was higher than that of patients with low expression of miR-802(P<0.05).The 3-year overall survival rate of patients with high expression of RAB23 was significantly lower than that of patients with low expression of RAB23(P<0.05).Multivariate analysis showed that high Gleason score,low expression of miR-802 and high expression of RAB23 were independent risk factors for adverse prognosis(P<0.05).The expression levels of miR-802 and RAB23 in tumor tissues were negatively correlated(P<0.05).Conclusion:The expression of miR-802 is low and RAB23 is high in prostate cancer tissues.They are related to T stage,lymph node metastasis,Gleason score,PSA level and 3-year overall survival rate.High Gleason score,low expression of miR-802 and high expression of RAB23 are independent risk factors for adverse prognosis.
作者 高永亮 张卫星 GAO Yongliang;ZHANG Weixing(Department of Urology,Xingyang People's Hospital,Henan Xingyang 450100,China;Department of Urology,First Affiliated Hospital of Zhengzhou University,Henan Zhengzhou 450100,China)
机构地区 荥阳市人民医院泌尿外科 郑州大学第一附属医院泌尿外科
出处 《现代肿瘤医学》 CAS 2021年第1期89-94,共6页 Journal of Modern Oncology
关键词 miR-802 RAB23 前列腺癌 临床病理参数 预后 miR-802 RAB23 prostate cancer clinicopathological parameters prognosis
分类号 R737.25 [医药卫生—肿瘤]
  • 相关文献

参考文献6

二级参考文献47

  • 1Jochems C, Tucker JA, Tsang KY, et al. A combination trial of vac- cine plus ipilimumab in metastatic castration - resistant prostate cancer patients : immunecorrelates [ J ]. Cancer Immunol Immunoth- er, 2014,63(4) :407 -418. 被引量：1
  • 2Guo W, Liu R, Bhardwaj G, et al. Targeting Btk/Etk of prostate cancer ceils by a novel dual inhibitor [ J ]. Cell Death Dis, 2014, 5 : e1409. 被引量：1
  • 3Arcangeli S, Pinzi V, Arcangeti G. Epidemiology of prostate cancer and treatment remarks [J]. World J Radiol, 2012, 4 (6) : 241-246. DOI : 10.4329/wjr.v4.i6.241. 被引量：1
  • 4Torte LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012 [J]. CA Cancer J Clin, 2015, 65 (2) : 87-108. DOI: 10.3322/ caac.21262. 被引量：1
  • 5Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013 [J]. JAMA Oncol, 2015, 1 (4) : 505-527. DOI: 10.100 l/jamaoncol.2015.0735. 被引量：1
  • 6Murray CJL, Barber RM, Foreman K J, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition [J]. Lancet, 2015, 386 (10009) : 2145-2191. DOI: 10.1016/S0140-6736( 15 )61340-X. 被引量：1
  • 7Zhou MG, Wang HD, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013:a systematic subnational analysis for the Global Burden of Disease Study 2013 [Jl. Lancet, 2016,387(10015) :251-272. DOI: 10.1016/S0140-6736 ( 15)00551-6. 被引量：1
  • 8Forouzanfar MH, Alexander L, Anderson HR, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 [J]. Lancet, 2015, 386 (10010) : 2287-2323. DOI: 10.1016/ S0140-6736( 15 )00128-2. 被引量：1
  • 9Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1 160 sequelae of 289 diseases and injuries 1990- 2010: a systematic analysis for the Global Burden of Disease Study 2010 [J]. Lancet, 2012, 380 (9859) : 2163-2196. DOI: 10.1016/S0140-6736( 12 )61729-2. 被引量：1
  • 10Siegel R, Ma JM, Zou ZH, et al. Cancer statistics, 2014 [J]. CA Cancer J C1in,2014,64( 1 ) :9-29. DOI: 10.3322/caac.21208. 被引量：1

共引文献121

现代肿瘤医学
2021年 第1期
202103读书月活动
维普数据出版直通车
今日学术
投稿分析
职称考试

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈